Focus on human microbiome to fight liver cirrhosis
22 European institutions join forces in MICROB-PREDICT to improve the prevention and treatment of chronic liver disease (cirrhosis). We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to acute-on-chronic liver failure (ACLF), and a patient’s individual treatment response. Based on such biomarkers, we strive to develop novel diagnostic tools for earlier and better patient stratification and to establish personalised and effective treatment strategies.
MICROB-PREDICT presents microbiome-based results at IHMC Congress in Rome
Saeed Shoaie (KCL), Benjamin Lelouvier (Vaiomer), Jonel Trebicka (EFCLIF / UKM), Peer Bork (EMBL) and Lindsey Edwards (KCL) present details on the prediction power of MICROB-PREDICT for late-stage liver disease at the IHMC Congress in Rome. “Microbiome can predict outcome and decompensation in liver cirrhosis.” explained Peer Bork. Benjamin Lelouver emphasized that results from MICROB-PREDICT stem from “the likely the most comprehensively microbiome-characterized cohort to date, MUCOSA-PREDICT”. Coordinator Jonel Trebicka is happy about the well-attended MICROB-PREDICT session plus posters of our fellows Peter Treit (MPI) and Marisa Metzger (EMBL).
More newsMICROB-PREDICT makes a splash at EASL 2024
It was a firework of MICROB-PREDICT results and discussions at this year's EASL Congress in fashionable Milan, Italy, from 5-8 June. Project sessions included the extremely well-attended Networking Session at the Cirrhosis & Complications Track Hub on Wednesday, 5 June, the Investigator Meeting and the high-quality Poster Tour on Thursday, 6 June, the Innovations Meeting with industry stakeholders plus the Patient Event on Friday, 7 June, and a privately organised dinner for our ALB-Trial investigators as gratitude for their fantastic work. Thank you, EASL, for the great organisation and to everyone who presented new outcomes to the hepatology community!
More newsMICROB-PREDICT project video
Focus on human microbiome to fight liver cirrhosis: 22 European institutions joined forces in January 2019 to improve the prevention and treatment of chronic liver disease (cirrhosis) within the MICROB-PREDICT project. We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis) and decompensated cirrhosis progresses to acute-on-chronic liver failure (ACLF), and individual treatment responses of patients. Coordinator Jonel Trebicka gives a brief overview of the project in this video.
More news